Inhibrx Shares Outstanding 2020-2022 | INBX

Inhibrx shares outstanding from 2020 to 2022. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Inhibrx Annual Shares Outstanding
(Millions of Shares)
2021 38
2020 25
2019 18
Inhibrx Quarterly Shares Outstanding
(Millions of Shares)
2022-09-30 39
2022-06-30 39
2022-03-31 39
2021-12-31 38
2021-09-30 38
2021-06-30 38
2021-03-31 38
2020-12-31 25
2020-09-30 27
2020-06-30 18
2020-03-31 18
2019-12-31
2019-09-30 18
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.094B $0.007B
Inhibrx Inc. is a clinical-stage biotechnology company. The company's pipeline is focused on oncology and orphan diseases. Inhibrx Inc. is based in SAN DIEGO.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $153.147B 9.34
GSK (GSK) United Kingdom $71.894B 8.95
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.086B 18.92
Ginkgo Bioworks Holdings (DNA) United States $3.531B 0.00
Myovant Sciences (MYOV) United Kingdom $2.613B 0.00
Arcus Biosciences (RCUS) United States $1.618B 24.29
Biohaven (BHVN) United States $1.266B 0.00
Emergent Biosolutions (EBS) United States $0.645B 5.07
ADC Therapeutics SA (ADCT) Switzerland $0.378B 0.00
Ambrx Biopharma (AMAM) United States $0.078B 0.00
Enzo Biochem (ENZ) United States $0.067B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00
Gelesis Holdings (GLS) United States $0.022B 0.00